Free Trial
→ Goldman Sachs just told you what to buy (most people missed it) (From Behind the Markets) (Ad)tc pixel Free KOD Stock Alerts

Kodiak Sciences (KOD) Financials

Kodiak Sciences logo
$36.00 -0.23 (-0.63%)
As of 05/26/2026 04:00 PM Eastern
Compare
Annual Income Statements for Kodiak Sciences

Annual Income Statements for Kodiak Sciences

This table shows Kodiak Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -17 -53 -68 -47 -133 -267 -334 -260 -176 -230
Consolidated Net Income / (Loss)		 -17 -28 -41 -47 -133 -267 -334 -260 -176 -230
Net Income / (Loss) Continuing Operations		 -17 -53 -68 -47 -133 -267 -334 -260 -176 -230
Total Pre-Tax Income 		-17 -53 -62 -47 -133 -267 -334 -260 -176 -230
Total Operating Income		 -17 -26 -26 -49 -136 -267 -341 -277 -187 -234
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 17 51 53 49 136 267 341 277 187 234
Selling, General & Admin Expense		 3.10 3.50 7.58 12 29 50 74 71 61 52
Research & Development Expense		 14 22 19 38 107 217 268 206 126 182
Total Other Income / (Expense), net		 0.02 -2.42 -9.59 1.83 2.91 0.06 7.56 17 11 4.42
Interest Expense		 0.01 1.19 5.52 0.01 0.03 0.05 0.02 0.01 0.00 0.00
Interest & Investment Income		 - 0.03 0.62 1.57 2.97 0.30 7.07 17 11 4.52
Other Income / (Expense), net		 0.03 -1.26 -4.69 0.27 -0.03 -0.19 0.50 0.11 -0.51 -0.10
Basic Earnings per Share		 ($2.38) ($3.72) ($2.77) ($1.25) ($2.91) ($5.16) ($6.39) ($4.97) ($3.35) ($4.32)
Weighted Average Basic Shares Outstanding		 7.21M 7.52M 14.98M 37.85M 45.74M 51.79M 52.25M 52.41M 52.58M 53.21M
Diluted Earnings per Share		 ($2.38) ($3.72) ($2.77) ($1.25) ($2.91) ($5.16) ($6.39) ($4.97) ($3.35) ($4.32)
Weighted Average Diluted Shares Outstanding		 7.21M 7.52M 14.98M 37.85M 45.74M 51.79M 52.25M 52.41M 52.58M 53.21M
Weighted Average Basic & Diluted Shares Outstanding		 7.21M 7.52M 14.98M 37.85M 45.74M 51.79M 52.34M 52.51M 52.75M 61.85M

Quarterly Income Statements for Kodiak Sciences

This table shows Kodiak Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -50 -60 -43 -45 -44 -44 -57 -54 -61 -57 -58
Consolidated Net Income / (Loss)		 -50 -60 -43 -45 -44 -44 -57 -54 -61 -57 -58
Net Income / (Loss) Continuing Operations		 -50 -60 -43 -45 -44 -44 -57 -54 -61 -57 -58
Total Pre-Tax Income 		-50 -60 -43 -45 -44 -44 -57 -54 -61 -57 -58
Total Operating Income		 -55 -63 -46 -48 -47 -46 -59 -56 -62 -57 -60
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 55 63 46 48 47 46 59 56 62 57 60
Selling, General & Admin Expense		 18 17 16 15 15 14 15 13 12 12 11
Research & Development Expense		 36 47 30 33 32 32 44 43 50 45 49
Total Other Income / (Expense), net		 4.49 3.86 3.02 2.87 2.69 2.07 1.61 1.20 0.90 0.72 1.62
Interest & Investment Income		 4.54 3.90 3.35 2.95 2.71 2.13 1.60 1.24 0.92 0.76 1.64
Other Income / (Expense), net		 -0.04 -0.04 -0.34 -0.09 -0.03 -0.06 0.01 -0.04 -0.02 -0.04 -0.02
Basic Earnings per Share		 ($0.95) ($1.14) ($0.82) ($0.86) ($0.84) ($0.83) ($1.09) ($1.03) ($1.16) ($1.04) ($0.94)
Weighted Average Basic Shares Outstanding		 52.46M 52.41M 52.51M 52.55M 52.62M 52.58M 52.75M 52.78M 52.86M 53.21M 61.86M
Diluted Earnings per Share		 ($0.95) ($1.14) ($0.82) ($0.86) ($0.84) ($0.83) ($1.09) ($1.03) ($1.16) ($1.04) ($0.94)
Weighted Average Diluted Shares Outstanding		 52.46M 52.41M 52.51M 52.55M 52.62M 52.58M 52.75M 52.78M 52.86M 53.21M 61.86M
Weighted Average Basic & Diluted Shares Outstanding		 52.47M 52.51M 52.53M 52.61M 52.62M 52.75M 52.76M 52.82M 53.05M 61.85M 62.58M

Annual Cash Flow Statements for Kodiak Sciences

This table details how cash moves in and out of Kodiak Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -17 -8.23 87 124 739 -213 -541 95 -118 42
Net Cash From Operating Activities		 -16 -18 -29 -39 -83 -182 -206 -154 -117 -136
Net Cash From Continuing Operating Activities		 -16 -18 -29 -39 -83 -182 -206 -154 -117 -136
Net Income / (Loss) Continuing Operations		 -17 -28 -41 -47 -133 -267 -334 -260 -176 -230
Consolidated Net Income / (Loss)		 -17 -28 -41 -47 -133 -267 -334 -260 -176 -230
Depreciation Expense		 0.26 0.55 0.49 0.54 0.48 1.00 3.80 18 19 18
Amortization Expense		 0.00 1.16 5.48 0.13 3.73 7.79 6.19 6.80 8.00 7.99
Non-Cash Adjustments To Reconcile Net Income		 0.27 1.54 13 6.11 31 62 105 89 61 62
Changes in Operating Assets and Liabilities, net		 0.56 7.04 -6.39 1.44 15 14 12 -7.35 -28 5.37
Net Cash From Investing Activities		 -0.77 -0.21 -0.58 -137 105 -39 -337 249 -0.76 -0.51
Net Cash From Continuing Investing Activities		 -0.77 -0.21 -0.58 -137 105 -39 -337 249 -0.76 -0.51
Purchase of Property, Plant & Equipment		 -0.77 -0.21 -0.08 -0.44 -3.81 -17 -37 -41 -0.38 -0.51
Purchase of Investments		 - 0.00 0.00 -151 -86 0.00 -428 -49 0.00 0.00
Sale and/or Maturity of Investments		 - 0.00 0.00 14 198 25 138 340 0.00 0.00
Other Investing Activities, net		 0.00 0.00 -0.50 0.00 -3.18 -46 -9.73 -0.08 -0.38 0.00
Net Cash From Financing Activities		 -0.12 9.64 116 300 717 8.18 1.90 0.03 0.50 178
Net Cash From Continuing Financing Activities		 -0.12 9.64 116 300 717 8.18 1.90 0.03 0.50 178
Issuance of Common Equity		 0.00 0.00 84 298 612 0.48 0.17 0.18 0.11 173
Other Financing Activities, net		 -0.05 -0.09 -0.04 2.12 5.72 7.70 1.72 -0.15 0.39 5.16
Cash Interest Paid		 0.01 0.02 0.02 0.01 0.03 0.02 0.02 0.01 0.00 0.00

Quarterly Cash Flow Statements for Kodiak Sciences

This table details how cash moves in and out of Kodiak Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -33 -60 -40 -27 -21 -30 -29 -35 -32 138 -40
Net Cash From Operating Activities		 -33 -32 -40 -26 -21 -30 -29 -35 -33 -39 -40
Net Cash From Continuing Operating Activities		 -33 -32 -40 -26 -21 -30 -29 -35 -33 -39 -40
Net Income / (Loss) Continuing Operations		 -50 -60 -43 -45 -44 -44 -57 -54 -61 -57 -58
Consolidated Net Income / (Loss)		 -50 -60 -43 -45 -44 -44 -57 -54 -61 -57 -58
Depreciation Expense		 5.00 4.73 4.70 4.70 4.69 4.63 4.60 4.59 4.59 4.54 4.11
Amortization Expense		 1.97 1.93 1.94 1.99 2.01 2.06 2.13 1.94 1.95 1.97 2.23
Non-Cash Adjustments To Reconcile Net Income		 14 23 19 19 15 8.62 18 16 14 13 12
Changes in Operating Assets and Liabilities, net		 -3.67 -2.53 -22 -6.64 1.28 -1.27 3.85 -2.54 7.99 -2.43 -0.35
Net Cash From Investing Activities		 -0.23 -28 -0.17 -0.26 -0.21 -0.12 -0.27 -0.13 -0.06 -0.04 -0.94
Net Cash From Continuing Investing Activities		 -0.23 -28 -0.17 -0.26 -0.21 -0.12 -0.27 -0.13 -0.06 -0.04 -0.94
Purchase of Property, Plant & Equipment		 -0.23 -27 -0.02 -0.05 -0.18 -0.12 -0.27 -0.13 -0.06 -0.04 -0.94
Other Investing Activities, net		 - -0.31 -0.14 -0.21 -0.03 - 0.00 - - - 0.00
Net Cash From Financing Activities		 -0.01 -0.12 0.04 0.06 - 0.40 0.12 0.12 0.81 177 0.62
Net Cash From Continuing Financing Activities		 -0.01 -0.12 0.04 0.06 - 0.40 0.12 0.12 0.81 177 0.62
Other Financing Activities, net		 -0.01 -0.18 0.04 - - 0.36 0.12 0.04 0.81 4.19 0.62

Annual Balance Sheets for Kodiak Sciences

This table presents Kodiak Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 3.24 92 359 1,067 904 667 479 336 352
Total Current Assets		 1.60 90 339 972 735 486 289 172 215
Cash & Equivalents		 1.40 88 212 944 732 190 286 168 210
Prepaid Expenses		 0.20 2.20 2.75 3.03 3.30 7.07 3.80 3.86 4.95
Plant, Property, & Equipment, net		 1.51 1.10 1.00 5.14 41 56 120 102 85
Total Noncurrent Assets		 0.14 0.64 19 90 128 124 70 61 51
Other Noncurrent Operating Assets		 0.14 0.64 6.94 90 128 124 70 61 51
Total Liabilities & Shareholders' Equity		 3.24 92 359 1,067 904 667 479 336 352
Total Liabilities		 22 5.36 14 207 241 230 214 185 194
Total Current Liabilities		 9.16 4.83 12 31 65 52 42 26 46
Accounts Payable		 3.36 1.05 2.62 8.65 12 9.13 14 3.92 13
Accrued Expenses		 5.80 3.78 8.66 20 48 33 18 11 21
Other Current Liabilities		 - 0.00 0.43 2.37 3.93 9.93 9.77 11 12
Total Noncurrent Liabilities		 13 0.53 1.80 175 176 178 172 160 149
Other Noncurrent Operating Liabilities		 2.89 0.53 1.80 175 176 178 172 160 149
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -69 87 345 861 663 436 266 150 157
Total Preferred & Common Equity		 -69 87 345 861 663 436 266 150 157
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -69 87 345 861 663 436 266 150 157
Common Stock		 0.59 198 503 1,152 1,222 1,330 1,418 1,479 1,716
Retained Earnings		 -69 -111 -158 -291 -558 -892 -1,153 -1,329 -1,559

Quarterly Balance Sheets for Kodiak Sciences

This table presents Kodiak Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 590 548 435 402 373 298 257 218 306
Total Current Assets		 387 351 252 225 202 143 108 76 175
Cash & Equivalents		 379 346 246 219 198 139 104 72 170
Prepaid Expenses		 8.29 5.26 5.59 5.40 4.63 3.83 3.75 3.69 5.73
Plant, Property, & Equipment, net		 130 125 116 111 107 98 93 89 82
Total Noncurrent Assets		 73 72 67 66 63 57 55 53 49
Other Noncurrent Operating Assets		 73 72 67 66 63 57 55 53 49
Total Liabilities & Shareholders' Equity		 590 548 435 402 373 298 257 218 306
Total Liabilities		 251 245 194 187 187 189 186 194 194
Total Current Liabilities		 74 71 25 21 24 31 31 42 50
Accounts Payable		 12 39 2.49 1.87 3.29 6.54 5.06 10 11
Accrued Expenses		 54 23 13 9.44 11 13 15 20 27
Other Current Liabilities		 7.85 9.02 9.61 9.89 10 11 11 12 12
Total Noncurrent Liabilities		 177 174 169 166 163 157 155 152 144
Other Noncurrent Operating Liabilities		 177 174 169 166 163 157 155 152 144
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 338 302 241 215 185 109 70 24 112
Total Preferred & Common Equity		 338 302 241 215 185 109 70 24 112
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 338 302 241 215 185 109 70 24 112
Common Stock		 1,381 1,395 1,437 1,455 1,470 1,495 1,511 1,526 1,729
Retained Earnings		 -1,043 -1,093 -1,196 -1,241 -1,285 -1,386 -1,441 -1,502 -1,617

Annual Metrics And Ratios for Kodiak Sciences

This table displays calculated financial ratios and metrics derived from Kodiak Sciences' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 36,829,857.00 37,058,168.00 44,803,447.00 51,717,286.00 52,309,154.00 52,472,291.00 - 53,048,428.00
DEI Adjusted Shares Outstanding		 0.00 0.00 36,829,857.00 37,058,168.00 44,803,447.00 51,717,286.00 52,309,154.00 52,472,291.00 - 53,048,428.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -1.84 -1.28 -2.97 -5.16 -6.38 -4.96 - -4.34
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -48.62% -0.08% -92.33% -173.20% -96.05% -28.03% 23.81% 36.28% -29.58%
EBIT Growth		 0.00% -56.37% -15.99% -57.51% -178.05% -96.45% -27.55% 18.68% 32.41% -25.15%
NOPAT Growth		 0.00% -48.80% -3.34% -86.51% -176.49% -96.35% -27.83% 18.76% 32.62% -25.44%
Net Income Growth		 0.00% -63.06% -48.35% -14.29% -181.00% -100.60% -25.03% 21.97% 32.36% -30.51%
EPS Growth		 0.00% -56.30% 25.54% 54.87% -132.80% -77.32% -23.84% 22.22% 32.60% -28.96%
Operating Cash Flow Growth		 0.00% -10.02% -64.44% -34.84% -113.12% -118.48% -13.27% 25.32% 23.91% -15.93%
Free Cash Flow Firm Growth		 0.00% 0.00% -255.11% -21.30% 130.88% -2,325.16% -16.49% 17.86% 38.88% 2.53%
Invested Capital Growth		 0.00% 0.00% 86.06% -98.31% -3,740.42% 36.99% 37.28% 53.87% 9.83% -195.06%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -16.27% -28.02% -21.76% 5.84% 5.16% 9.67% -5.81%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -15.67% -29.36% -20.89% 5.46% 3.50% 8.40% -5.04%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -16.12% -29.10% -20.92% 5.27% 3.71% 8.43% -5.05%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -2.06% -30.32% -21.13% 6.37% 4.03% 8.04% -5.81%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -635.29% -25.43% -18.62% 6.58% 4.05% 8.47% -5.11%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -13.46% -8.16% -23.23% -21.31% 1.88% 12.90% 1.82% -7.35%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -57.52% -25.86% 1.09% -0.44% 23.53% -7.52%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -208.65% -9.68% 6.50% 26.09% 54.39% -42.36% -8.55%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 52.26% 66.48% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.04% 199.62% 200.69% 96.81% 97.84% 99.91% 97.93% 93.97% 94.05% 98.07%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 149.22% -121.69% -21.92% -22.07% -35.04% -60.72% -74.22% -84.70% -149.49%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 547.90% -32.33% -21.92% -22.07% -35.04% -60.72% -74.22% -84.70% -149.49%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 40.64% -47.73% -13.71% -15.46% -40.25% -76.54% 0.00% -117.25% 0.00%
Net Operating Profit after Tax (NOPAT)		 -12 -18 -18 -34 -95 -187 -239 -194 -131 -164
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% 236.25% -57.65% -5.93% -5.75% -9.42% -15.67% -17.36% -20.02% -34.87%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -54.79% -73.04% -87.03% -104.25%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -17 -27 -31 -49 -136 -267 -341 -277 -187 -234
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -17 -25 -25 -48 -132 -258 -331 -252 -161 -208
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 3.01 7.72 7.65 6.61 0.86 0.60 3.48 9.42
Price to Tangible Book Value (P/TBV)		 0.00 0.00 3.01 7.72 7.65 6.61 0.86 0.60 3.48 9.42
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 550.30 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 -0.53 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 -0.53 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -0.46 -1.17 -1.01 -1.09 -1.12 -1.10 -1.09 -1.09 -1.23
Leverage Ratio		 0.00 -0.17 1.40 1.04 1.18 1.29 1.43 1.63 1.96 2.23
Compound Leverage Factor		 0.00 -0.35 2.81 1.01 1.16 1.29 1.40 1.53 1.84 2.19
Debt to Total Capital		 0.00% -112.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% -112.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% -568.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 781.11% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 -0.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 -0.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 -0.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 -0.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 -57.50 27.61 118.47 19.37 9.97 -1.81 -4.21 -5.17 -3.25
Noncontrolling Interest Sharing Ratio		 0.00% -267.17% 73.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 0.17 18.74 28.97 30.93 11.36 9.26 6.93 6.72 4.72
Quick Ratio		 0.00 0.15 18.29 28.73 30.84 11.31 9.12 6.84 6.57 4.61
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -7.67 -27 -33 10 -227 -264 -217 -133 -129
Operating Cash Flow to CapEx		 -2,081.32% -8,447.37% -37,219.23% -8,957.89% -2,187.41% -1,070.16% -557.68% -372.87% -31,285.07% -26,879.05%
Free Cash Flow to Firm to Interest Expense		 0.00 -6.47 -4.93 -4,129.50 408.00 -4,829.12 -14,688.29 -16,704.98 0.00 0.00
Operating Cash Flow to Interest Expense		 -2,674.50 -14.90 -5.26 -4,893.25 -3,337.12 -3,878.09 -11,469.94 -11,860.23 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -2,803.00 -15.08 -5.27 -4,947.88 -3,489.68 -4,240.47 -13,526.67 -15,041.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 -10 -1.42 -2.82 -108 -68 -43 -20 -18 -52
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -10 8.77 -1.40 -105 40 25 23 1.94 -35
Enterprise Value (EV)		 0.00 149 173 2,318 5,613 3,653 -104 -126 356 1,273
Market Capitalization		 90 90 261 2,666 6,582 4,385 375 160 524 1,483
Book Value per Share		 $0.00 ($9.15) $2.36 $9.32 $19.21 $12.83 $8.34 $5.07 $2.86 $2.97
Tangible Book Value per Share		 $0.00 ($9.15) $2.36 $9.32 $19.21 $12.83 $8.34 $5.07 $2.86 $2.97
Total Capital		 0.00 -8.80 87 345 861 663 436 266 150 157
Total Debt		 0.00 9.92 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 9.92 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 8.53 -88 -348 -969 -732 -479 -286 -168 -210
Capital Expenditures (CapEx)		 0.77 0.21 0.08 0.44 3.81 17 37 41 0.38 0.51
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -8.96 -2.63 -8.96 -28 -61 -45 -38 -22 -41
Debt-free Net Working Capital (DFNWC)		 0.00 -7.56 86 328 941 670 434 248 146 169
Net Working Capital (NWC)		 0.00 -7.56 86 328 941 670 434 248 146 169
Net Nonoperating Expense (NNE)		 5.13 10 23 13 38 80 95 66 45 66
Net Nonoperating Obligations (NNO)		 0.00 8.53 -88 -348 -969 -732 -479 -286 -168 -210
Total Depreciation and Amortization (D&A)		 0.26 1.71 5.97 0.67 4.21 8.79 9.99 25 27 26
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($2.77) ($1.25) ($2.91) ($5.16) ($6.39) ($4.97) ($3.35) ($4.32)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 36.91M 44.42M 51.16M 51.93M 52.25M 52.41M 52.58M 53.21M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($2.77) ($1.25) ($2.91) ($5.16) ($6.39) ($4.97) ($3.35) ($4.32)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 36.91M 44.42M 51.16M 51.93M 52.25M 52.41M 52.58M 53.21M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($2.77) ($1.25) ($2.91) ($5.16) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 14.98M 37.85M 45.74M 51.79M 52.34M 52.51M 52.75M 61.85M
Normalized Net Operating Profit after Tax (NOPAT)		 -12 -18 -18 -34 -95 -187 -239 -194 -131 -164
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -2,854.33 -22.60 -5.63 -6,115.63 -5,441.48 -5,685.98 -18,937.56 -21,323.92 0.00 0.00
NOPAT to Interest Expense		 -2,000.95 -15.08 -3.35 -4,304.13 -3,808.20 -3,977.36 -13,275.85 -14,932.67 0.00 0.00
EBIT Less CapEx to Interest Expense		 -2,982.83 -22.78 -5.64 -6,170.25 -5,594.04 -6,048.36 -20,994.28 -24,504.69 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -2,129.45 -15.25 -3.36 -4,358.75 -3,960.76 -4,339.74 -15,332.57 -18,113.44 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Kodiak Sciences

This table displays calculated financial ratios and metrics derived from Kodiak Sciences' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 52,453,163.00 52,472,291.00 52,508,602.00 52,534,947.00 52,614,729.00 - 52,748,343.00 52,763,541.00 52,821,689.00 53,048,428.00 61,847,870.00
DEI Adjusted Shares Outstanding		 52,453,163.00 52,472,291.00 52,508,602.00 52,534,947.00 52,614,729.00 - 52,748,343.00 52,763,541.00 52,821,689.00 53,048,428.00 61,847,870.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.95 -1.13 -0.82 -0.86 -0.84 - -1.09 -1.03 -1.16 -1.07 -0.94
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 38.27% 19.45% 42.61% 47.30% 15.99% 30.30% -31.67% -18.42% -39.73% -28.89% -2.15%
EBIT Growth		 31.41% 13.68% 37.64% 43.36% 14.45% 27.09% -27.31% -15.57% -33.69% -24.35% -1.25%
NOPAT Growth		 31.43% 14.44% 38.28% 43.44% 14.44% 27.13% -28.27% -15.69% -33.71% -24.41% -1.19%
Net Income Growth		 35.09% 15.52% 39.19% 43.74% 12.12% 25.89% -33.51% -20.38% -39.85% -28.64% -1.21%
EPS Growth		 35.37% 15.56% 39.26% 43.79% 11.58% 27.19% -32.93% -19.77% -38.10% -25.30% 13.76%
Operating Cash Flow Growth		 38.28% 41.46% 16.14% 36.86% 35.43% 6.73% 26.57% -30.88% -55.42% -30.95% -37.60%
Free Cash Flow Firm Growth		 25.36% 12.77% 42.72% 19.82% -20.15% 49.16% 68.68% 85.95% 87.71% 83.88% 26.45%
Invested Capital Growth		 25.26% 53.87% 83.46% 88.26% 71.11% 9.83% -502.73% -617.84% -286.95% -195.06% -101.44%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 39.43% -19.31% 29.96% -4.14% 3.45% 1.02% -32.32% 6.34% -13.91% 8.70% -4.87%
EBIT Q/Q Growth		 35.74% -16.27% 26.84% -3.62% 2.94% 0.90% -27.75% 5.94% -12.28% 7.83% -4.01%
NOPAT Q/Q Growth		 35.76% -16.28% 27.33% -4.19% 2.82% 0.97% -27.92% 6.03% -12.33% 7.86% -4.05%
Net Income Q/Q Growth		 37.64% -19.02% 27.69% -4.83% 2.60% -0.36% -30.28% 5.48% -13.15% 7.68% -2.51%
EPS Q/Q Growth		 37.91% -20.00% 28.07% -4.88% 2.33% 1.19% -31.33% 5.50% -12.62% 10.34% 9.62%
Operating Cash Flow Q/Q Growth		 21.91% 1.60% -22.83% 33.10% 20.14% -42.13% 3.30% -19.25% 5.17% -19.76% -1.60%
Free Cash Flow Firm Q/Q Growth		 38.74% -27.74% 16.75% -23.08% 8.20% 45.95% 48.72% 44.79% 19.65% 29.13% -133.95%
Invested Capital Q/Q Growth		 -7.61% 54.39% 76.02% 0.23% -164.76% -42.36% -60.29% -18.82% -42.72% -8.55% -9.43%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 91.69% 93.85% 92.77% 93.85% 94.19% 95.39% 97.29% 97.77% 98.53% 98.68% 97.26%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -69.42% -74.22% -73.45% -71.50% -78.57% -84.70% -108.92% -140.33% -207.92% -149.49% -208.80%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -69.42% -74.22% -73.45% -71.50% -78.57% -84.70% -108.92% -140.33% -207.92% -149.49% -208.80%
Return on Equity Simple (ROE_SIMPLE)		 -89.75% 0.00% -96.50% 0.00% 0.00% 0.00% -175.14% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -38 -44 -32 -34 -33 -32 -41 -39 -44 -40 -42
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.69% -3.96% -3.24% -3.86% -4.16% -5.19% -8.41% -9.56% -13.20% -8.74% -10.63%
Return On Investment Capital (ROIC_SIMPLE)		 - -16.69% -13.37% -15.66% -17.61% -21.51% -37.99% -55.28% -184.22% -25.55% -37.33%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -55 -63 -46 -48 -47 -46 -59 -56 -62 -57 -60
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -48 -57 -40 -41 -40 -40 -52 -49 -56 -51 -53
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.31 0.60 1.15 0.58 0.74 3.48 1.36 2.80 36.50 9.42 21.03
Price to Tangible Book Value (P/TBV)		 0.31 0.60 1.15 0.58 0.74 3.48 1.36 2.80 36.50 9.42 21.03
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.13 -1.09 -1.05 -1.08 -1.11 -1.09 -1.10 -1.14 -1.29 -1.23 -1.39
Leverage Ratio		 1.63 1.63 1.70 1.79 1.89 1.96 2.09 2.31 2.83 2.23 2.73
Compound Leverage Factor		 1.49 1.53 1.57 1.68 1.78 1.87 2.04 2.26 2.78 2.20 2.66
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -2.28 -2.73 -2.72 -3.72 -4.22 -3.78 -6.25 -7.58 -7.73 -1.59 -0.25
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.96 6.93 10.12 10.59 8.42 6.72 4.62 3.48 1.78 4.72 3.54
Quick Ratio		 4.88 6.84 9.89 10.34 8.22 6.57 4.50 3.36 1.70 4.61 3.42
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -53 -67 -56 -69 -63 -34 -18 -9.70 -7.79 -5.52 -13
Operating Cash Flow to CapEx		 -14,497.35% -117.30% -180,000.00% -54,067.35% -11,753.33% -24,250.00% -10,769.26% -26,069.92% -54,800.00% -91,576.74% -4,247.24%
Free Cash Flow to Firm to Interest Expense		 -10,553.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -6,552.80 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -6,598.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -43 -20 -4.73 -4.72 -12 -18 -29 -34 -48 -52 -57
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 15 23 24 35 31 1.94 -24 -29 -36 -35 -29
Enterprise Value (EV)		 -251 -126 30 -96 -61 356 9.11 93 793 1,273 2,188
Market Capitalization		 94 160 276 123 137 524 148 197 865 1,483 2,358
Book Value per Share		 $5.77 $5.07 $4.59 $4.08 $3.52 $2.86 $2.06 $1.33 $0.45 $2.97 $2.11
Tangible Book Value per Share		 $5.77 $5.07 $4.59 $4.08 $3.52 $2.86 $2.06 $1.33 $0.45 $2.97 $2.11
Total Capital		 302 266 241 215 185 150 109 70 24 157 112
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -346 -286 -246 -219 -198 -168 -139 -104 -72 -210 -170
Capital Expenditures (CapEx)		 0.23 27 0.02 0.05 0.18 0.12 0.27 0.13 0.06 0.04 0.94
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -66 -38 -19 -16 -19 -22 -27 -27 -39 -41 -44
Debt-free Net Working Capital (DFNWC)		 280 248 227 203 178 146 112 77 33 169 126
Net Working Capital (NWC)		 280 248 227 203 178 146 112 77 33 169 126
Net Nonoperating Expense (NNE)		 12 15 11 12 11 12 16 15 18 17 16
Net Nonoperating Obligations (NNO)		 -346 -286 -246 -219 -198 -168 -137 -104 -72 -210 -170
Total Depreciation and Amortization (D&A)		 6.97 6.66 6.65 6.68 6.70 6.68 6.73 6.54 6.54 6.52 6.34
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.95) ($1.14) ($0.82) ($0.86) ($0.84) ($0.83) ($1.09) ($1.03) ($1.16) ($1.04) ($0.94)
Adjusted Weighted Average Basic Shares Outstanding		 52.46M 52.41M 52.51M 52.55M 52.62M 52.58M 52.75M 52.78M 52.86M 53.21M 61.86M
Adjusted Diluted Earnings per Share		 ($0.95) ($1.14) ($0.82) ($0.86) ($0.84) ($0.83) ($1.09) ($1.03) ($1.16) ($1.04) ($0.94)
Adjusted Weighted Average Diluted Shares Outstanding		 52.46M 52.41M 52.51M 52.55M 52.62M 52.58M 52.75M 52.78M 52.86M 53.21M 61.86M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 52.47M 52.51M 52.53M 52.61M 52.62M 52.75M 52.76M 52.82M 53.05M 61.85M 62.58M
Normalized Net Operating Profit after Tax (NOPAT)		 -38 -44 -32 -34 -33 -32 -41 -39 -44 -40 -42
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -10,907.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -7,630.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -10,952.80 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -7,675.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

A concise, investor-friendly snapshot of Kodiak Sciences (KOD) over the last four years, focusing on cash flow, income, and the balance sheet. Items are grouped by likely impact on the stock and ordered with positives first, then neutral, then negatives.

  • Q4 2025 equity financing was substantial: Issuance of Common Equity = $173,058,000, contributing to a Net Cash From Continuing Financing Activities of about $177,245,000 and a Net Change in Cash of roughly $137,824,000, markedly boosting liquidity for the period.
  • Ongoing financing support in 2025: Net Cash From Continuing Financing Activities shows recurring inflows in several quarters (Q2 2025: +$120,000; Q3 2025: +$813,000; Q4 2025: +$177,245,000), underscoring reliance on equity to fund operations.
  • Non-cash items help reconcile earnings to cash flow: Depreciation ($4.54M in Q4 2025), Amortization ($1.97M), and Non-Cash Adjustments To Reconcile Net Income (~$13.28M) in Q4 2025 provide non-cash support to the cash flow statement.
  • Revenue remains effectively zero across 2024–2025 quarters, indicating no product revenue yet (neutral for stock impact since this is a consistent, visible characteristic of Kodiak’s quarterlies).
  • Operating cash burn remains material in 2025: Net Cash From Continuing Operating Activities ranged from about -$29.1M to -$39.4M per quarter, signaling ongoing cash consumption from operations.
  • Net income remains negative across 2025: Consolidated Net Income / Loss for the quarter runs around -$54M to -$62M (Q4 2025: -$56.7M; Q3 2025: -$61.5M; Q2 2025: -$54.3M; Q1 2025: -$57.5M).
  • Balance sheet shows liabilities outpacing equity in many periods: Total Liabilities approximately $194M in Q3 2025 versus Total Equity around $23.7M, indicating significant leverage relative to equity.
  • Cumulative retained earnings are deeply negative: Retained Earnings frequently hover around or below -$1.3B to -$1.5B in recent periods, reflecting sustained cumulative losses.
  • Revenue absence contrasted with high R&D spend: 2025 periods show substantial R&D outlays, with ongoing operating expenses concentrated in R&D and SG&A, which is typical for a biotech in development and may not translate to near-term profitability.
  • Asset base and capitalization dynamics: Total Assets declined through 2025 (from ~$298M in Q1 2025 to ~$218M in Q3 2025), with liquidity heavily reliant on equity financing (notably the Q4 2025 equity raise), suggesting liquidity is externally driven rather than self-generated from operations.
05/27/26 02:34 AM ETAI Generated. May Contain Errors.

Kodiak Sciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Kodiak Sciences' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Kodiak Sciences' net income appears to be on an upward trend, with a most recent value of -$229.97 million in 2025, rising from -$17.13 million in 2016. The previous period was -$176.21 million in 2024. See where experts think Kodiak Sciences is headed by visiting Kodiak Sciences' forecast page.

Kodiak Sciences' total operating income in 2025 was -$234.39 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $234.39 million

Over the last 9 years, Kodiak Sciences' total revenue changed from $0.00 in 2016 to $0.00 in 2025, a change of 0.0%.

Kodiak Sciences' total liabilities were at $194.15 million at the end of 2025, a 4.8% increase from 2024, and a 783.9% increase since 2017.

In the past 8 years, Kodiak Sciences' cash and equivalents has ranged from $1.40 million in 2017 to $944.40 million in 2020, and is currently $209.86 million as of their latest financial filing in 2025.

Over the last 9 years, Kodiak Sciences' book value per share changed from 0.00 in 2016 to 2.97 in 2025, a change of 296.7%.


Related Companies

Financial statements for NASDAQ:KOD last updated on 5/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Read now. Do not delete. You’ve been warned.
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...
Porter & Company | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel